You are here: Industry Insights > Samsung Biologics

News List

South Korean regulator publishes final ruling on Samsung BioLogics’ accounting violations pharmaceutical-technology
November 15, 2018
South Korea’s financial regulator Securities and Futures Commission (SFC) has issued its final decision regarding Samsung BioLogic’s alleged breach of accounting rules.
Samsung BioLogics’ End-to-End service to maximize client satisfaction cphi-online
November 14, 2018
Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung BioLogics provides an end-to-end service for contracted biopharmaceutical
Samsung BioLogics reaches milestone with FDA nod for production of mAb at South Korean plant fiercepharma
July 27, 2018
South Korea’s quickly growing biologics CDMO, Samsung BioLogics, has won FDA approval for its first finished product at the second of three plants that have been built in rapid succession.
Samsung BioLogics Receives the first FDA DP approval biospectrumasia
July 26, 2018
Samsung BioLogics has 16 total global approvals for manufacturing Drug Substance in Plant 1 and 2
Samsung BioLogics’ shares down $6bn after accounting furore pharmafile
May 03, 2018
Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of accounting rules by the country’s financial regulator.
Samsung BioLogics’ stock slides after regulators claim accounting rules infraction fiercepharma
May 03, 2018
Contract drug manufacturing giant Samsung BioLogics saw its stock slide, losing almost $6 billion in market value Wednesday, after South Korean securities ...
Samsung BioLogics Receives the 1st FDA Approval at the World's Largest Plant prnasia
October 12, 2017
With the first license of its second plant from the FDA, Samsung BioLogics is now able to manufacture commercial Biologics Drug Substance at its second plant in addition to its first plant which has 30,000 liters of capacity.
Sun Pharma ties up with Samsung BioLogics expressbpd
July 05, 2017
Samsung BioLogics will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis
Samsung BioLogics says next plant in US possible koreaherald
March 28, 2017
Saving time and lowering costs are decisive factors for a contract manufacturing operator that produces biopharmaceutical products. And Samsung BioLogics is confident of achieving both.

Previous page 1 2 3 4 5 6 Next page